Physician profile
Mallory Lynch
NPI 1720508120
$3,650.85
in general payments reported to CMS, 2019-2025
32 companies · $539 in 2025
The $539 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $836 · 2022: $765 · 2023: $1,051 · 2024: $460 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,050.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $478.16 | 2021-2025 | |
| Novo Nordisk INC | $382.99 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $368.14 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $291.31 | 2022-2025 | |
| Glaxosmithkline, LLC. | $258.90 | 2021-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.78 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $197.03 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.59 | 2021-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $117.82 | 2024-2025 | Voquezna |
| Amgen INC. | $114.20 | 2023-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $105.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $100.78 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $96.93 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $90.92 | 2024-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $68.96 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $68.94 | 2021-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company LTD. | $59.49 | 2022 | |
| Abbott Laboratories | $52.04 | 2021-2023 | Freestyle Libre |
| Sumitomo Pharma America, INC. | $51.05 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $50.48 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Corcept Therapeutics | $47.55 | 2025 | Korlym |
| Seqirus USA INC | $46.39 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Janssen Pharmaceuticals, INC | $43.91 | 2022-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $40.25 | 2022 | |
| Astellas Pharma US INC | $28.43 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.92 | 2025 | Caplyta |
| Scpharmaceuticals INC. | $22.82 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $20.37 | 2024 | Eliquis |
| Kyowa Kirin, INC. | $19.07 | 2025 | |
| Lundbeck LLC | $17.65 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $15.67 | 2024 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mallory Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.